Physician
Oncology
Dr. Mark B. Blick, DO
|
|
Give Review
Mark Blick is an expert in the field of Oncology. He researched medicine at Wayne State University School of Medicine. Wayne State University School of Medicine is ranked 63 in research and 85 in primary care medicine Mark B. Blick, DO is a published physician. He has 63 papers published. The most current publication "Transforming growth factor-alpha production and autoinduction in a colorectal carcinoma cell line (DiFi) with an amplified epidermal growth factor receptor gene." Doctor Mark B. Blick, DO accepts all Medicare patients.
Publications
- Rapid in situ hybridization technique using 16S rRNA segments for detecting and differentiating the closely related gram-positive organisms Bacillus polymyxa and Bacil...
- Differential expression of metastasis-associated cell surface glycoproteins and mRNA in a murine large cell lymphoma.
- Analysis of the epidermal growth factor receptor gene in fresh human head and neck tumors.
- Ovarian (corpus luteum) hemorrhage during anticoagulation therapy.
- Transforming growth factor-alpha production and autoinduction in a colorectal carcinoma cell line (DiFi) with an amplified epidermal growth factor receptor gene.
- Durable complete remissions after 2'-deoxycoformycin treatment in patients with hairy cell leukemia resistant to interferon alpha.
- Suppression by retinoic acid of epidermal growth factor receptor autophosphorylation and glycosylation in cultured human head and neck squamous carcinoma cells.
- Frequent loss of heterozygosity on chromosomes 6q, 11, and 17 in human ovarian carcinomas.
- Detection of a surface antigen on NIH3T3 cells transfected with a human leukemia oncogene.
- Expression of abl and other oncogenes is independent of metastatic potential in Abelson virus-transformed malignant murine large cell lymphoma.
- Allele loss at the c-Ha-ras1 locus in human ovarian cancer.
- c-K-ras codon 12 GGT-CGT point mutation. An infrequent event in human lung cancer.
- Oncogene expression in human leukemia.
- Proto-oncogene expression in human normal bone marrow.
- Oncogene expression in adenocarcinomas of the colon and in colon tumor-derived cell lines.
- Immunohistochemical analysis of P-glycoprotein expression correlated with chemotherapy resistance in locally advanced breast cancer.
- Comparison of oncogene expression in human normal bone marrow and leukemia.
- In vitro analysis of cell populations involved in Hodgkin''s disease lesions and in the characteristic T cell immunodeficiency.
- SIS/PDGF-B expression in benign and malignant human breast lesions.
- Aberrant expression of the K-ras proto-oncogene in B-cell malignancies.
- Phase I study of recombinant tumor necrosis factor in cancer patients.
- Heterogeneity of non-Hodgkin's lymphoma probed by nucleic acid cytometry.
- Identification of human immunodeficiency virus hybridizing sequences in the peripheral blood of a patient with systemic lupus erythematosus.
- Characterization of an amsacrine-resistant line of human leukemia cells. Evidence for a drug-resistant form of topoisomerase II.
- Characterization of the DiFi rectal carcinoma cell line derived from a familial adenomatous polyposis patient.
- Clinical evaluation of a DNA probe assay for the Philadelphia (Ph1) translocation in chronic myelogenous leukemia.
- A novel c-abl protein product in Philadelphia-positive acute lymphoblastic leukaemia.
- Molecular characteristics of chronic myelogenous leukemia in blast crisis.
- Aberrant oncogene expression in uncultured human sarcoma and melanoma.
- Multiple restriction fragment length polymorphisms of the human epidermal growth factor receptor gene.
- Reduction to homozygosity at the SIS/PDGF-2 locus in human mesenchymal tumors.
- Association of the Epstein-Barr virus with lymphoepithelioma of the thymus.
- Effect of phorbol ester treatment on drug-induced, topoisomerase II-mediated DNA cleavage in human leukemia cells.
- A phase I trial of intravenously-administered recombinant tumor necrosis factor-alpha in cancer patients.
- Bcl-1 gene rearrangements in B cell lymphoma.
- Suppression of c-myc and c-myb expression in myeloid cell lines treated with recombinant tumor necrosis factor-alpha.
- Analysis of the estrogen receptor gene structure in human breast cancer.
- Lack of breakpoint cluster region rearrangement in marrow fibroblasts of patients with Philadelphia chromosome-positive chronic myelogenous leukemia.
- Rearrangement and enhanced expression of c-myc oncogene in fresh tumor cells obtained from a patient with acute lymphoblastic leukemia.
- Molecular analysis of interferon-induced suppression of Philadelphia chromosome in patients with chronic myeloid leukemia.
- Alteration and abnormal expression of the c-myc oncogene in human multiple myeloma.
- Effect of differentiation-inducing agents on oncogene expression in a chronic myelogenous leukemia cell line.
- Tumor necrosis factor and c-fos expression in human peripheral-blood monocytes: expression is dependent on stage of in vitro differentiation.
- Identification of molecular variants of p210bcr-abl in chronic myelogenous leukemia.
- C-sis and C-abl expression in chronic myelogenous leukemia and other hematologic malignancies.
- Significance and correlations of molecular analysis results in patients with Philadelphia chromosome-negative chronic myelogenous leukemia and chronic myelomonocytic l...
- Tumor proliferative fraction in solid malignant neoplasms. A comparative study of Ki-67 immunostaining and flow cytometric determinations.
- c-erbB-2 amplification in node-negative human breast cancer.
- Amplified and overexpressed epidermal growth factor receptor gene in uncultured primary human breast carcinoma.
- Alternative 5'' end of the bcr-abl transcript in chronic myelogenous leukemia.
- Philadelphia-negative chronic myelogenous leukemia with breakpoint cluster region rearrangement: molecular analysis, clinical characteristics, and response to therapy.
- Effect of retinoids on the release and gene expression of tumor necrosis factor-alpha in human peripheral blood monocytes.
- Analysis of breakpoints within the bcr gene and their correlation with the clinical course of Philadelphia-positive chronic myelogenous leukemia.
- The gene located at chromosome 18 band q21 is rearranged in uncultured diffuse lymphomas as well as follicular lymphomas.
- HLA class II antigen associated invariant chain gene expression in malignant lymphoma.
- Expression of c-fos, c-myb, and c-myc in human monocytes: correlation with monocytic differentiation.
- The c-abl, bcr and C lambda genes are amplified in a cell line but not in the uncultured cells from a patient with chronic myelogenous leukemia.
- Rearrangement in the breakpoint cluster region and the clinical course in Philadelphia-negative chronic myelogenous leukemia.
- Lithium chloride stimulates human monocytes to secrete tumor necrosis factor/cachectin.
- Philadelphia chromosome without breakpoint cluster region rearrangement in a case of Lennert''s lymphoma of suppressor phenotype.
- Clonal nature of Philadelphia chromosome-positive and -negative chronic myelogenous leukemia by DNA hybridization analyses.
- Ki-67 immunostaining in node-negative stage I/II breast carcinoma. Significant correlation with prognosis.
Schools
University Of Health SciencesCollege Of Osteopathic Medicine
Detroit Osteo Hospital
Wayne State University
MD Anderson Hospital
Conditions Treated
- Anemia
Doctors Specialties
- Hematology
- Oncology
Accepted Insurances
- Aetna HMO
- Choice Plus POS II
- American Republic
- Blue Card PPO
- Blue Advantage HMO
- Blue Choice
- CHAMPVA
- Cigna HMO
- Cigna PPO
- Great West Healthcare-Cigna PPO
- LocalPlus
- Open Access Plus
- Commercial Insurance Company
- CoreSource
- Coventry Health Care
- Health Alliance
- HealthFirst
- Choice Care PPO
- Preferred PPO
- Mail Handlers Benefit Plan (MHBP)
- Medicare MCR
- MultiPlan PPO
- PHCS Network PPO
- Choice Plus POS
- Navigate HMO
- Navigate POS
- Options PPO
- United Healthcare
Education
-
University of Texas MD Anderson Cancer Center -
Wayne State University School of Medicine -
Kansas City University of Medicine and Biosciences
Drug Facts
| NPI NUMBER | 1811912041 | |
| NPPES Provider LastName | BLICK | |
| NPPES Provider FirstName | MARK | |
| NPPES Provider ZIPCode | 774013500 | |
| NPPES Provider State | TX | |
| Specialty Description | Internal Medicine | |
| Total Claim Count | 18071.0 | |
| Distinct Opioid Count | 5.0 | |
| Opioid Claim Count | 1330.0 | |
| Percent Opioid Claims | 7.36 |
Helpful Reviews
Medicare Facts
| National Provider Identifier [NPI] | 1811912041 |
| Last Name Of The Provider | BLICK |
| First Name Of The Provider | MARK |
| View All |